+28.3%
ACN vs MRNA
+537.9%
-509.6%
-68.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | -3.6% | -0.5% | -3.9% |
| 7D | -4.8% | -9.0% | +4.2% | -4.4% |
| 30D | +1.9% | +137.2% | -135.3% | -5.9% |
| 3M | +3.9% | +194.8% | -190.9% | -5.7% |
| 6M | -15.0% | +167.2% | -182.2% | -22.5% |
| YTD | -31.9% | +375.9% | -407.8% | -40.5% |
| 1Y | -28.5% | +465.2% | -493.7% | -38.4% |
| 3Y | -41.9% | +30.4% | -72.3% | -46.6% |
| 5Y | -42.9% | -66.8% | +24.0% | -46.0% |
| All | +28.3% | +537.9% | -509.6% | +10.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling